Dimensional Fund Advisors
KRYS icon

Dimensional Fund Advisors’s Krystal Biotech KRYS Stock Holding History

Dimensional Fund Advisors’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$177M Buy
476,038
+7,048
+2% +$2.11M 0.03% 750
2026
Q1 		$121M Sell
468,990
-23,978
-5% -$6.38M 0.03% 935
2025
Q4 		$122M Sell
492,968
-40,996
-8% -$8.63M 0.03% 928
2025
Q3 		$94.3M Buy
533,964
+28,075
+6% +$4.2M 0.02% 1120
2025
Q2 		$69.5M Sell
505,889
-28,030
-5% -$4.12M 0.02% 1292
2025
Q1 		$96.3M Sell
533,919
-54,680
-9% -$9.2M 0.02% 1007
2024
Q4 		$92.2M Sell
588,599
-11,662
-2% -$2.07M 0.02% 1098
2024
Q3 		$109M Buy
600,261
+19,809
+3% +$3.82M 0.03% 967
2024
Q2 		$107M Buy
580,452
+7,537
+1% +$1.27M 0.03% 911
2024
Q1 		$102M Buy
572,915
+22,109
+4% +$3.07M 0.03% 933
2023
Q4 		$68.3M Buy
550,806
+30,169
+6% +$3.35M 0.02% 1215
2023
Q3 		$60.4M Buy
520,637
+34,040
+7% +$4.15M 0.02% 1219
2023
Q2 		$57.1M Buy
486,597
+24,507
+5% +$2.5M 0.02% 1255
2023
Q1 		$37M Buy
+462,090
New +$36.3M 0.01% 1553
2022
Q3 		$25M Buy
358,837
+82,914
+30% +$5.99M 0.01% 1694
2022
Q2 		$18.1M Buy
275,923
+13,460
+5% +$837K 0.01% 1926
2022
Q1 		$17.5M Buy
262,463
+111,822
+74% +$6.98M 0.01% 2033
2021
Q4 		$10.5M Sell
150,641
-13,223
-8% -$770K ﹤0.01% 2289
2021
Q3 		$8.56M Sell
163,864
-49,848
-23% -$2.95M ﹤0.01% 2398
2021
Q2 		$14.5M Buy
213,712
+68,380
+47% +$4.77M ﹤0.01% 2195
2021
Q1 		$11.2M Buy
145,332
+76,988
+113% +$5.6M ﹤0.01% 2279
2020
Q4 		$4.1M Buy
68,344
+21,390
+46% +$1.07M ﹤0.01% 2594
2020
Q3 		$2.02M Buy
46,954
+11,096
+31% +$482K ﹤0.01% 2741
2020
Q2 		$1.49M Buy
+35,858
New +$1.73M ﹤0.01% 2840
2019
Q4 		– Sell
-14,270
Closed -$496K – 3395
2019
Q3 		$496K Buy
+14,270
New +$638K ﹤0.01% 3138

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Dimensional Fund Advisors's KRYS Position: Q2 2026 in Review

Dimensional Fund Advisors increased its Krystal Biotech (KRYS) stake by 1.5% in Q2 2026, buying an estimated $2.11M and bringing the position to 476,038 shares worth $177M. The position accounts for 0.03% of the portfolio, ranked #750.

Dimensional Fund Advisors first reported a position in KRYS in Q3 2019 and has held it in 25 quarters since. 424 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Dimensional Fund Advisors held 476,038 shares of Krystal Biotech worth $177M as of Q2 2026.
  • Dimensional Fund Advisors bought 7,048 Krystal Biotech shares in Q2 2026, an estimated $2.11M.
  • Krystal Biotech made up 0.03% of Dimensional Fund Advisors's portfolio in Q2 2026, its #750 holding.
  • Dimensional Fund Advisors first reported a position in Krystal Biotech in Q3 2019 and has held it in 25 quarters since.
  • 424 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Dimensional Fund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.